Evidence map›Paper›PMID 19816688›Full record

ReviewRheumatology international2010

Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

Anne-Christine Bay-Jensen, Suzi Hoegh-Madsen, Erik Dam, Kim Henriksen, Bodil Cecillie Sondergaard, Philippe Pastoureau, Per Qvist, Morten A Karsdal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Aggrecan: Approaches to Study Biophysical and Biomechanical Properties.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  18. Article
  19. Article
  20. Effects of human articular cartilage constituents on simultaneous diffusion of cationic and nonionic contrast agents.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anne-Christine Bay-JensenNordic Bioscience A/S, Herlev Hovedgade 207, Herlev, Denmark. acbj@nordicbioscience.com
Suzi Hoegh-Madsen
Erik Dam
Kim Henriksen
Bodil Cecillie Sondergaard
Philippe Pastoureau
Per Qvist
Morten A Karsdal
Nordic Bioscience (Denmark) · DKServier (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a disease of the entire joint. Different treatment strategies for OA have been proposed and tested clinically without the desired efficacy. One reason for the scarcity of current chondroprotective agents may be the insufficient understanding of the patho-physiology of the joint and whether the joint damage is reversible or irreversible. In this review, we compile emerging data on cellular and pathological aspects of OA, and ask whether these data could give clue to when cartilage degradation is reversible and whether a point-of-no-return exists. We highlight different stages of OA, and speculate whether different intervention strategies (e.g. DMOAD vs. SMOADs) may only be efficacious at distinct stages of OA.

Indexed as

Antirheumatic AgentsCartilage, ArticularDisease ProgressionHumansJointsOsteoarthritisRecovery of FunctionAntirheumatic Agents

Identifiers

PMID19816688
OpenAlexW2048131429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.